M
Meadowhawk Biolabs
Meadowhawk biolabs is a preclinical Contract Research Organization (CRO), partners with you to advance your drug discovery and development work
About Meadowhawk Biolabs
Meadowhawk Biolabs is a preclinical Contract Research Organization (CRO) that specializes in bioanalytical, pharmacokinetic, and pharmacology studies. In simpler terms, they help other companies test and develop new drugs. Their clients are typically pharmaceutical and biotech companies that are in the early stages of developing new treatments and therapies.
Operating in the pharmaceutical research market, Meadowhawk Biolabs offers a unique business model where they act as an extension of their clients' labs. They provide expert scientists, state-of-the-art equipment, and precise procedures to help their clients advance their drug discovery and development work. This model allows their clients to focus on their core competencies while Meadowhawk Biolabs handles the complex and time-consuming research processes.
The company generates revenue by charging their clients for the research services they provide. They pride themselves on delivering reliable results with immediacy and precision, which makes them a valuable partner for companies looking to bring new treatments to market quickly and efficiently.
Meadowhawk Biolabs was founded by industry veterans with a broad range of expertise, from biology and industrial engineering to information technology. This diverse background allows them to respond quickly and skillfully to their clients' project requirements, ensuring successful outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Marlborough, United States
- Employees
- 88
- Open positions
- 2
- Dealroom signal
- 82.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2024 | $5M | $47M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Mar 2023 | $9.3M | $37M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Meadowhawk Biolabs is 1.7K monthly website visits, down 46.9% over the last three months. Meadowhawk Biolabs's team grew 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Meadowhawk Biolabs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Meadowhawk Biolabs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







